UPC APP 546231/2023

Jul 11, 2023·EP3666797: ANTIGEN BINDING PROTEINS TO PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 (PCSK9)

Case details: Status
Written Phase
Action
Generic
Category
Other Procedural
Parties: Claimants
Name not displayed for GDPR reasons. Represented by Oswin RIDDERBUSCH
Reps: Oswin Ridderbusch
Respondents
Sanofi-Aventis Deutschland GmbH
Amgen Inc.
Reps: Daniel Wise; Koen Bijvank
Division: Munich CD
Judges: Ulrike Voß
Andras Kupecz
Casper Struve
Technology: Biotechnology
Language: English

Documents

Document title	Date	Public
Outcome of the Order	2023-09-20	Not public
Order rejecting Rule 262.1(b) application dated 20 September 2023	2023-09-20	Not public
2023.08.30 ACT459505-2023 Sanofi - No comments on file inspection request (signed)	2023-08-30	Not public
2023.08.30 ACT459505-2023 Sanofi - No comments on file inspection request (signed)	2023-08-30	Not public
2023.08.30 ACT459505-2023 Sanofi - No comments on file inspection request (signed)	2023-08-30	Not public
Preliminary Order 262(1)(b) dated 28 August 2023	2023-08-28	Not public
Comments in response to the Preliminary Order of August 4, 2023 submitted under Rule 264 RoP	2023-08-18	Not public
Preliminary Order 262(1)(b) dated 4 August 2023	2023-08-04	Not public
Claimants' Reply to File Inspection Request	2023-07-28	Not public
Claimants' Reply to File Inspection Request	2023-07-28	Not public
Claimants' Reply to File Inspection Request	2023-07-28	Not public
Defendant's Comments pursuant to R. 264 RoP	2023-07-28	Not public
Preliminary Order 262(1)(b) dated 14 July 2023	2023-07-14	Not public
Application for file inspection	2023-07-10	Not public